Metabolism of the taxanes including nab-paclitaxel

Bibliography

• MCWani, HLTaylor, MEWall, et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-7
   PubMed Web of Science ®Google Scholar
• FLavelle, FGueritte-Voegelein, DGuenard. [Taxotere: from yew’s needles to clinical practice]. Bull Cancer 1993;80:326-38
   PubMedGoogle Scholar
• ACMita, LJDenis, EKRowinsky, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009;15:723-30
   PubMed Web of Science ®Google Scholar
• SCisternino, FBourasset, YArchimbaud, et al. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br J Pharmacol 2003;138:1367-75
   PubMed Web of Science ®Google Scholar
• RAJibodh, JSLagas, BNuijen, et al. Taxanes: old drugs, new oral formulations. Eur J Pharmacol 2013;717:40-6
   PubMed Web of Science ®Google Scholar
• CPBelani, JSLee, MASocinski, et al. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol 2005;16:1069-75
   PubMed Web of Science ®Google Scholar
• JASparano, MWang, SMartino, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358:1663-71
   PubMed Web of Science ®Google Scholar
• GWSledge, DNeuberg, PBernardo, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003;21:588-92
   PubMed Web of Science ®Google Scholar
• Adu Bois, HJLuck, WMeier, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:1320-9
   PubMed Web of Science ®Google Scholar
• MKParmar, JALedermann, NColombo, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099-106
   PubMed Web of Science ®Google Scholar
• ARahman, KRKorzekwa, JGrogan, et al. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994;54:5543-6
   PubMed Web of Science ®Google Scholar
• RVaclavikova, PSoucek, LSvobodova, et al. Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs. Drug Metab Dispos 2004;32:666-74
   PubMed Web of Science ®Google Scholar
• BMonsarrat, EChatelut, IRoyer, et al. Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug Metab Dispos 1998;26:229-33
   PubMed Web of Science ®Google Scholar
• CABurkhart, MKavallaris, SBand Horwitz. The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 2001;1471:O1-9
   PubMed Web of Science ®Google Scholar
• FAndre, CHatzis, KAnderson, et al. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 2007;13:2061-7
   PubMed Web of Science ®Google Scholar
• STanaka, TNohara, MIwamoto, et al. Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer. Cancer Chemother Pharmacol 2009;64:341-6
   PubMed Web of Science ®Google Scholar
• DSSonnichsen, CAHurwitz, CBPratt, et al. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 1994;12:532-8
   PubMed Web of Science ®Google Scholar
• MOKarlsson, VMolnar, AFreijs, et al. Pharmacokinetic models for the saturable distribution of paclitaxel. Drug Metab Dispos 1999;27:1220-3
   PubMed Web of Science ®Google Scholar
• Ovan Tellingen, MTHuizing, VRPanday, et al. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 1999;81:330-5
   PubMed Web of Science ®Google Scholar
• LGianni, CMKearns, AGiani, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995;13:180-90
   PubMed Web of Science ®Google Scholar
• ESykes, KWoodburn, DDecker, DKessel. Effects of cremophor EL on distribution of Taxol to serum lipoproteins. Br J Cancer 1994;70:401-4
   PubMed Web of Science ®Google Scholar
• ASparreboom, Lvan Zuylen, EBrouwer, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999;59:1454-7
   PubMed Web of Science ®Google Scholar
• GNKumar, UKWalle, KNBhalla, TWalle. Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res Commun Chem Pathol Pharmacol 1993;80:337-44
   PubMedGoogle Scholar
• MTHuizing, JBVermorken, HRosing, et al. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. Ann Oncol 1995;6:699-704
   PubMed Web of Science ®Google Scholar
• PHWiernik, ELSchwartz, JJStrauman, et al. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987;47:2486-93
   PubMed Web of Science ®Google Scholar
• MJoerger, SKraff, ADHuitema, et al. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. Clin Pharmacokinet 2012;51:607-17
   PubMed Web of Science ®Google Scholar
• MJoerger, ADHuitema, MTHuizing, et al. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. Br J Clin Pharmacol 2007;64:622-33
   PubMed Web of Science ®Google Scholar
• APVenook, MJEgorin, GLRosner, et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: cancer and Leukemia Group B 9264. J Clin Oncol 1998;16:1811-19
   PubMed Web of Science ®Google Scholar
• MJoerger, JHBeumer. Cancer treatment in patients with hepatic dysfunction. In: Cancer treatments in special clinical situations 2013. ESMO Handbook Series; ESMO Press, Viganello-Lugano (Switzerland) 2013
   Google Scholar
• MJoerger, ADHuitema, DHvan den Bongard, et al. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clin Cancer Res 2006;12:2150-7
   PubMed Web of Science ®Google Scholar
• AAMiller, GLRosner, MJEgorin, et al. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: cancer and Leukemia Group B Study 9763. Clin Cancer Res 2004;10:8325-31
   PubMed Web of Science ®Google Scholar
• DRMould, GFFleming, KMDarcy, DSpriggs. Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study. Br J Clin Pharmacol 2006;62:56-70
   PubMed Web of Science ®Google Scholar
• SMielke, ASparreboom, SMSteinberg, et al. Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 2005;11:4843-50
   PubMed Web of Science ®Google Scholar
• MTHuizing, GGiaccone, LJvan Warmerdam, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J Clin Oncol 1997;15:317-29
   PubMed Web of Science ®Google Scholar
• MJoerger, ADHuitema, DJRichel, et al. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res 2007;13:6410-18
   PubMed Web of Science ®Google Scholar
• TCHuang, TCCampbell. Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: a meta-analysis. Cancer Treat Rev 2012;38:613-17
   PubMed Web of Science ®Google Scholar
• WSchuette, TBlankenburg, WGuschall, et al. Multicenter randomized trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/carboplatin. Clin Lung Cancer 2006;7:338-43
   PubMed Web of Science ®Google Scholar
• CPBelani, SRamalingam, MCPerry, et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 2008;26:468-73
   PubMed Web of Science ®Google Scholar
• ADSeidman, DBerry, CCirrincione, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008;26:1642-9
   PubMed Web of Science ®Google Scholar
• NKatsumata, MYasuda, SIsonishi, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 2013;14:1020-6
   PubMed Web of Science ®Google Scholar
• NKatsumata, MYasuda, FTakahashi, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:1331-8
   PubMed Web of Science ®Google Scholar
• JChan, MBrady, RPenson, et al. Phase III trial of every-3-weeks paclitaxel vs. dose-dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT01167712). Int J Gynecol Cancer 2013;23:Suppl 1
   Google Scholar
• SPignata, GScambia, DKatsaros, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2014;15(4):396-405
   PubMed Web of Science ®Google Scholar
• MEde Jonge, HJvan den Bongard, ADHuitema, et al. Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. Clin Cancer Res 2004;10:2237-44
   PubMed Web of Science ®Google Scholar
• MHWoo, MVRelling, DSSonnichsen, et al. Phase I targeted systemic exposure study of paclitaxel in children with refractory acute leukemias. Clin Cancer Res 1999;5:543-9
   PubMed Web of Science ®Google Scholar
• HRoche, PFumoleau, MSpielmann, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006;24:5664-71
   PubMed Web of Science ®Google Scholar
• ERivera, JAMejia, BKArun, et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 2008;112:1455-61
   PubMed Web of Science ®Google Scholar
• FAShepherd, JDancey, RRamlau, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103
   PubMed Web of Science ®Google Scholar
• IFTannock, Rde Wit, WRBerry, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12
   PubMed Web of Science ®Google Scholar
• EVan Cutsem, VMMoiseyenko, STjulandin, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991-7
   PubMed Web of Science ®Google Scholar
• MRPosner, DMHershock, CRBlajman, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-15
   PubMed Web of Science ®Google Scholar
• WXQi, ZShen, FLin, et al. Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. Curr Med Res Opin 2013;29:117-25
   PubMed Web of Science ®Google Scholar
• UVaishampayan, REParchment, BRJasti, MHussain. Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology 1999;54:22-9
   PubMed Web of Science ®Google Scholar
• HWang, TVo, AHajar, et al. Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells. BMC Cancer 2014;14:37
   PubMed Web of Science ®Google Scholar
• ESAntonarakis, AJArmstrong. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2011;14:192-205
   PubMed Web of Science ®Google Scholar
• Lvan Zuylen, ASparreboom, Avan der Gaast, et al. Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. Eur J Cancer 2002;38:1090-9
   PubMed Web of Science ®Google Scholar
• PMFracasso, LJGoldstein, DPde Alwis, et al. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin Cancer Res 2004;10:7220-8
   PubMed Web of Science ®Google Scholar
• VGMartinez, RO’Connor, YLiang, MClynes. CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance. Br J Cancer 2008;98:564-70
   PubMed Web of Science ®Google Scholar
• IPastina, EGiovannetti, AChioni, et al. Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. BMC Cancer 2010;10:511
   PubMed Web of Science ®Google Scholar
• SJClarke, LPRivory. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999;36:99-114
   PubMed Web of Science ®Google Scholar
• WJLoos, SDBaker, JVerweij, et al. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin Pharmacol Ther 2003;74:364-71
   PubMed Web of Science ®Google Scholar
• RBruno, ROlivares, JBerille, et al. Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin Cancer Res 2003;9:1077-82
   PubMed Web of Science ®Google Scholar
• RBruno, DHille, ARiva, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998;16:187-96
   PubMed Web of Science ®Google Scholar
• JTabernero, MACliment, ALluch, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2004;15:1358-65
   PubMed Web of Science ®Google Scholar
• WSchuette, SNagel, TBlankenburg, et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 2005;23:8389-95
   PubMed Web of Science ®Google Scholar
• SDBaker, MZhao, CKLee, et al. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res 2004;10:1976-83
   PubMed Web of Science ®Google Scholar
• FKEngels, WJLoos, JMvan der Bol, et al. Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study. Clin Cancer Res 2011;17:353-62
   PubMed Web of Science ®Google Scholar
• JSde Bono, SOudard, MOzguroglu, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54
   PubMed Web of Science ®Google Scholar
• EGirard, SDitzler, DLee, et al. Efficacy of cabazitaxel in mouse models of pediatric brain tumors. Neuro Oncol 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• EPean, PDemolis, AMoreau, et al. The European Medicines Agency review of cabazitaxel (Jevtana(R)) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 2012;17:543-9
   PubMed Web of Science ®Google Scholar
• PVrignaud, DSemiond, PLejeune, et al. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin Cancer Res 2013;19:2973-83
   PubMed Web of Science ®Google Scholar
• GMFerron, YDai, DSemiond. Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2013;71:681-92
   PubMed Web of Science ®Google Scholar
• VDieras, ALortholary, VLaurence, et al. Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study. Eur J Cancer 2013;49:25-34
   PubMed Web of Science ®Google Scholar
• KPaal, JMuller, LHegedus. High affinity binding of paclitaxel to human serum albumin. Eur J Biochem 2001;268:2187-91
   PubMedGoogle Scholar
• GWatkins, ADouglas-Jones, RBryce, et al. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids 2005;72:267-72
   PubMed Web of Science ®Google Scholar
• MSinn, BVSinn, JKStriefler, et al. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Ann Oncol 2014;25:1025-32
   PubMed Web of Science ®Google Scholar
• MABookman, DDKloth, PEKover, et al. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol 1997;8:611-14
   PubMed Web of Science ®Google Scholar
• NKIbrahim, NDesai, SLegha, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8:1038-44
   PubMed Web of Science ®Google Scholar
• DDVon Hoff, TErvin, FPArena, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703
   PubMed Web of Science ®Google Scholar
• WJGradishar, DKrasnojon, SCheporov, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009;27:3611-19
   PubMed Web of Science ®Google Scholar
• MASocinski, IBondarenko, NAKaraseva, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012;30:2055-62
   PubMed Web of Science ®Google Scholar
• WSchubert, PGFrank, BRazani, et al. Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in vivo. J Biol Chem 2001;276:48619-22
   PubMed Web of Science ®Google Scholar
• NChen, YLi, AYe, et al. Population pharmacokinetics (PK) and exposure-neutropenia relationship of nab-paclitaxel (nab-P) in patients with solid tumors. J Clin Oncol 2014;32:abstract 2559
   Google Scholar
• NDesai, VTrieu, ZYao, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317-24
   PubMed Web of Science ®Google Scholar
• MYBiakhov, GVKononova, JIglesias, et al. nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study. Expert Opin Drug Saf 2010;9:515-23
   PubMed Web of Science ®Google Scholar
• MASocinski, GMManikhas, DLStroyakovsky, et al. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2010;5:852-61
   PubMed Web of Science ®Google Scholar
• KSaito, YKikuchi, KFujii, et al. Effect of paclitaxel on vascular endothelial growth factor (VEGF) and interleukin (IL)-8 in serum of patients with recurrent ovarian cancer: a comparison of weekly vs triweekly regimens. Targ Oncol 2006;1:86-9
   Web of Science ®Google Scholar
• JHBeumer. Without therapeutic drug monitoring, there is no personalized cancer care. Clin Pharmacol Ther 2013;93:228-30
   PubMed Web of Science ®Google Scholar